New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
07:22 EDTRXIIRXi Pharmaceuticals announces results of Phase 1 RXI-109 study
RXi Pharmaceuticals announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects. This drug candidate is a highly selective CTGF targeting sd-rxRNA compound that is administered through intradermal injections to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. In this study, 15 volunteers divided over 5 cohorts received single intradermal injections in a dose escalating manner, and blood was drawn at various time points to evaluate the distribution of the drug beyond the injected tissue, into the systemic circulation. Previous primate toxicology work with RXI-109 had shown that the peak blood levels obtained after intradermal injections with 10 mg/kg were approximately 3.5% of the peak levels obtained after intravenous injections with the same dose. With the different doses in the primate study, the dermal and systemic side effects in the animals were minimal. The calculated relative systemic exposure in the 15 volunteers was between 1 and 7% which is very similar to the systemic exposure in primates. As reported earlier, the drug was very well tolerated in all volunteers tested.
News For RXII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
07:51 EDTRXIIRXi Pharmaceuticals receives Orphan Drug Designation for Samcyprone from FDA
Subscribe for More Information
April 16, 2015
08:03 EDTRXIIRXi Pharmaceuticals granted orphan status for melanoma treatment
The FDA granted RXi Pharmaceuticals orphan status for its treatment of malignant melanoma stage IIB to IV Samcyprone.
April 14, 2015
09:13 EDTRXIIOn The Fly: Pre-market Movers.
UP AFTER EARNINGS: JPMorgan Chase (JPM), up 1%... Johnson & Johnson (JNJ), up marginally... Triangle Petroleum (TPLM), up 4.2%... Fastenal (FAST), up 5%. ALSO HIGHER: Brainstorm Cell Therapeutics (BCLI), up 13.5% after announcing that it will present NurOwn Phase 2a clinical data at the Academy of Neurology annual meeting... Builders FirstSource (BLDR), up 7.2% after being upgraded to Buy from Hold at Stifel... Solazyme (SZYM), up 7.5% after announcing a strategic agreement with Flotek (FTK)... Cleveland BioLabs (CBLI), up 6.8% after receiving funding recommendation from the Department of Defense... Nordic American Tanker (NAT), up 3.2% after raising quarterly dividend to 38c from 22c... Ocwen (OCN), up 3.8% after reporting preliminary fiscal 2014 results. DOWN AFTER EARNINGS: Wells Fargo (WFC), down just under 1%. ALSO LOWER: Norfolk Southern (NSC), down 5.8% after being downgraded to Hold from Buy at TD Securities... RXi Pharmaceuticals (RXII), down 14.3% after filing to sell $20M of common stock and warrants... Arrowhead Research (ARWR), down 4.5% after being downgraded to Hold from Buy at Jefferies.
April 13, 2015
17:25 EDTRXIIRXi Pharmaceuticals files to sell $20M of common stock, warrants
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use